Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT-IN: Optimal Perioperative Therapy for Incidental Gallbladder Cancer
NCT04559139Phase 3Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Feb 2021
- Primary completion
- Jul 2028
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine, Cisplatin micelle injection (HA132) in gallbladder cancer, sponsored by ECOG-ACRIN Cancer Research Group. Started Feb 2021; status: active, not recruiting.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)
03
Conditions
gallbladder cancer
Beyond the preview
Go deeper on NCT04559139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04559139.